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The Intergroup Exemestane Study (IES), an investigator-led study in 4724 postmenopausal 
patients with early breast cancer (ISRCTN11883920), has previously demonstrated that 
switching adjuvant endocrine therapy after 2-3 years tamoxifen to exemestane is associated 
with clinically relevant improvements in efficacy. Here we report the final efficacy analyses 
of this cohort.  
 
Patients and methods 
Patients who remained disease-free after 2-3 years of adjuvant tamoxifen were randomized to 
continue tamoxifen (T) or switch to exemestane (E) to complete a total of 5 years adjuvant 
endocrine therapy. Given the large number of non-breast cancer deaths now reported, breast-
cancer-free survival (BCFS), censoring intercurrent deaths, is the primary survival endpoint 
of interest. Analyses focus on patients with ER positive (+) or unknown tumors (n=4599). 
 
Results 
At the time of data snapshot, median follow-up was 120 months. In the ER+/unknown 
population, 1111 BCFS events were observed, 508/2294 (22.1%) and 603/2305 (26.2%) in E 
and T groups respectively, corresponding to absolute difference (E-T) at 10 years of 4.0% 
(95%CI 1.2%-6.7%), with hazard ratio (HR) of 0.81 (95% CI 0.72-0.92) favoring E. This 
difference remained in multivariable analysis adjusting for nodal status, prior use of HRT and 
chemotherapy (HR=0.80 (95%CI 0.71-0.90); p<0.001).   
 
A modest improvement in overall survival was seen with E, with absolute difference (E-T) at 
10 years in the ER+/unknown population of 2.1% (95%CI -0.5%-4.6%), HR=0.89 (95%CI 
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0.78-1.01, p=0.08). For the ITT population, absolute difference was 1.6% (95%CI -0.9%-
4.1%), HR=0.91 (95%CI 0.80-1.03, p=0.15).  
 
Conclusions 
The IES and contemporaneous studies have established that a strategy of switching to an 
aromatase inhibitor after 2-3 years of tamoxifen can lead to sustained benefits in terms of 






















Despite improvements in adjuvant treatment, breast cancer remains the most frequent cause 
of cancer-related death in women, with approximately 508,000 deaths reported worldwide in 
20111. For patients diagnosed with ER positive disease, risk of disease relapse remains for 
over 15 years after initial diagnosis, with recent research demonstrating the cumulative risk of 
relapse at 15 years to be comparable to that of ER negative patients in those receiving 
chemotherapy2.  
 
Aromatase inhibitors reduce recurrence rates and 10-year breast cancer mortality rates 
compared with tamoxifen, but the optimal way to schedule aromatase inhibitors is still 
debated3. 
 
The Intergroup Exemestane Study (IES) was an investigator-led, Pfizer sponsored trial 
assessing the impact on disease related outcome, adverse events, and quality of life of 
switching to exemestane after 2-3 years of tamoxifen compared with continuing to 5 years of 
tamoxifen4-11. The most recent update of efficacy analyses published in 2012 (data snapshot 
December 7, 2009) after a median follow-up of 91 months demonstrated that the highly 
statistically significant benefit of switching to exemestane on disease-free survival observed 
at initial publication was maintained, and this translated to a modest improvement in overall 
survival6.  
 
IES was the first trial published to describe the benefits of switching from tamoxifen to an AI 
(exemestane) at 2-3 years, and was one of the pivotal generation of trials assessing the role of 
aromatase inhibitors in combination with or as a replacement for standard tamoxifen 
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treatment3. Whether the strategy results in long-term sustained improvement in DFS or 
survival remains controversial, although our previous report suggested that his was the case6. 
 
Recent analyses of the ATAC trial have sought to identify clinical and biological factors 
associated with disease relapse after completion of endocrine therapy12,13. Nodal involvement 
and tumor size are the most important clinical factors for predicting relapse both during and 
post treatment completion in ER positive breast cancer patients14,15. The other aim of this 
study, therefore, was to establish which prognostic features were important in the IES trial, 
which employed a ‘switching’ strategy, especially after the end of endocrine therapy. 
  
Here we present the final efficacy analysis of the IES, along with exploratory analyses 




Details of trial design, eligibility criteria and study procedures have been presented 
previously4-6. Briefly, eligible patients were post-menopausal women with ER+/unknown 
primary invasive breast cancer who remained disease free and on treatment after 2-3 years of 
tamoxifen.  At randomisation women were allocated to continue tamoxifen (20 mg or [30 mg 
in Denmark] daily) or to switch to exemestane (25 mg daily) for the remainder of the 5 year 
endocrine therapy period. Timing of analyses was pre-planned, triggered by the last patient 
randomised reaching their 10 year follow-up. The current analysis includes all data received 




Efficacy analyses presented here have been performed on the main IES analysis population, 
which includes patients whose tumors were ER+ve (4052, 85.8%) plus those whose ER status 
remains unknown (547, 11.6%). Analyses exclude 125 patients (2.6%) with ER-negative 
disease, who would not have been eligible for the trial had their receptor status been known at 
trial entry. Intention to treat (ITT) analysis of OS is included for completeness. 
 
Statistical analysis 
The primary endpoint of the IES was DFS, defined as time from randomisation to local or 
distant breast cancer recurrence, new primary breast cancer or death without disease relapse 
(intercurrent death). As reported previously6, the proportion of patients experiencing 
intercurrent death has increased as the IES population ages, decreasing the sensitivity of DFS 
to detect differences between treatments in breast cancer outcome. Therefore we now regard 
breast cancer free survival (BCFS) in which intercurrent deaths are censored, as providing a 
more direct estimate of the treatment effect on breast cancer outcome in the long term.  Other 
secondary endpoints presented include overall survival (OS, defined as time from 
randomisation to death from any cause), breast cancer specific survival (BCSS, defined as 
time from randomisation to breast cancer death (including death from unknown cause and 
other cause after recurrence), time to contralateral breast cancer (CLB, defined as time to 
contralateral breast cancer with patients censored at time of non-breast second primary 
cancer) and time to distant recurrence (TTDR, defined as time to distant recurrence or death 
from breast cancer or unknown cause without prior recurrence).  
 
Kaplan-Meier plots, log-rank tests and Cox proportional hazards analyses were used to 
compare survival endpoints between randomised treatment groups.  Multivariable analysis 
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adjusting for known prognostic factors of nodal status, chemotherapy use and HRT use was 
also conducted.  
 
For description of the sites of first distant recurrence the following groupings were used: 
visceral, bone or soft tissue/nodal, with patients assigned to multiple groups where relevant.  
Progression of metastatic disease subsequent to the initial distant recurrence was ignored. 
Events where site of recurrence was unknown were excluded from this part of the analysis. 
 
The overall and age-related incidence of non-breast cancer second primary cancers was 
investigated to confirm the observation in our previous reports of a differential pattern 
according to randomised treatment5,6. For patients who reported more than one non-breast 
second primary cancer (n=6), the first reported event was included. Second primaries 
reported with no confirmed date of diagnosis were excluded (n=8). 
 
Competing risks analyses were undertaken to assess the impact of randomised treatment on 
breast cancer events (local recurrence, distant recurrence, CLB, ipsilateral breast cancer 
(ILB), and BC death or death from unknown cause) whilst allowing for “competing risks” of 
intercurrent death and non-breast second primary cancer. Patients were included depending 
on which event occurred first; breast cancer event or competing risk event.  Gray’s test was 
used to compare the two treatment groups with respect to breast cancer event in the presence 
of competing risks16. 
 
Landmark analyses were performed to investigate the factors related to distant recurrence 
after the end of endocrine therapy. TTDR was the endpoint of interest, with survival time 
being partitioned at 2.5 years, representing the approximate end of endocrine therapy in IES. 
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The impact of randomised treatment and a number of patient and tumor characteristics on 
TTDR after 2.5 years was assessed, both as single variables and together in a multivariable 
Cox proportional hazards model. 
 
Full adverse event4-7,11 and quality of life9,10 data have been reported previously and are 
therefore not included in this manuscript, but we present here an updated estimate of post-
treatment fracture incidence by treatment received. This includes all fractures occurring more 
than 6 months after treatment completion in patients who received at least 1 day of treatment, 
with events censored following relapse or new second primary cancer.  
 
Analyses were performed using STATA version 13.2, (STATA Corp, College Station, TX). 
All statistical tests were two-sided with p<0.05 considered statistically significant. 
 
Results 
Between 1998 and 2003, 4724 evaluable patients were randomised from 366 sites in 37 
countries. Of these, 4599 are known to be ER+ve or have unknown ER status (Figure 1).  
 
Patient characteristics have previously been reported and were well balanced between 
treatment groups5,6. In summary, 2089/4724 (44.2%) patients were node positive and 
1542/4724 (32.6%) patients had received adjuvant chemotherapy. Mean age at randomisation 
was 64.2 years (SD=8.2). At the time of data snapshot (04/09/2013) median follow-up in 
patients still known to be alive was 120.0 months (IQR: 114.8 to 122.0, range: 2.9 to 164.1), 
with current analysis based on over 39,000 women-years of follow-up. 74.7% of patients had 





In the ER+ve/unknown population, 1111/4599 patients have experienced a BCFS event 
(exemestane 508/2294 (22.1%), tamoxifen 603/2305 (26.2%)). A reduction in risk of breast 
cancer related events was observed with an absolute difference at 10 years of 4.0% (95% CI 
1.2% to 6.7%) and a hazard ratio of 0.81 (95% CI 0.72 to 0.92) in favor of switching to 
exemestane (Figure 2a).  
 
In the ER+ve/unknown population, 940/4599 patients have died (exemestane 445/2294 
(19.4%), tamoxifen 495/2305 (21.5%)). A modest improvement in OS was seen with 
exemestane, with an absolute survival difference at 10 years of 2.1% (95% CI -0.5% to 4.6%) 
and a hazard ratio of 0.89 (95% CI 0.78 to 1.01) in favor of switching to exemestane, Figure 
2b. The numerical difference in deaths was mainly seen in deaths due to breast cancer, with 
rates of intercurrent deaths similar between randomised treatment groups (Table 1). Results 
were similar when considering the ITT population (exemestane 467/2352 (19.9%), tamoxifen 
510/2372 (21.5%), HR=0.91 (95% CI 0.80 to 1.03), Figure 2c. 
 
In the ER+ve/unknown population, 659/4599 BCSS events were reported (exemestane 
303/2294 (13.2%), tamoxifen 356/2305 (15.4%)). Absolute BCSS difference at 10 years was 
2.3% (95% CI -0.0% to 4.6%) with a hazard ratio of 0.84 (95% CI 0.72 to 0.98) in favor of 
switching to exemestane, Figure 2d. 
 
1392 DFS events have been reported in ER+/unknown patients only (exemestane 650/2294 
(28.3%), tamoxifen 742/2305 (32.2%)). The highly significant improvement in DFS 
associated with switching to exemestane that we noted previously remains, with no 
convergence of survival curves seen (Figure 2e). This sustained benefit translated to an 
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absolute difference in the proportion remaining alive and disease-free at 10 years of 3.8% 
(95%CI 0.9%, 6.6%). This difference remained in multivariable analyses adjusting for nodal 
status, prior HRT use and prior chemotherapy (HR favoring switch to exemestane of 0.83 
(95%CI 0.75 to 0.93); p=0.001).   
 
Using competing risks methodology, investigating all outcomes in a single analysis, the 
cumulative incidence of intercurrent deaths was seen to increase steadily throughout the 
follow-up period and was comparable between randomised treatment groups (Figure 3). 
Considering breast cancer events (after adjustment for competing risks), the early benefit 
from switching to exemestane was maintained throughout follow-up (Gray’s test p=0.002).  
 
No statistically significant difference was seen between randomised groups in the number of 
patients reporting a new primary CLBC (exemestane 56; tamoxifen 75; HR=0.73, 95% CI 
0.52-1.03, Table 1) although the observed hazard ratio is consistent with other trials which 
have explored the additional preventative benefits of aromatase inhibitors compared with 
tamoxifen17. Numerically fewer non-breast second primary cancers were also reported with 
exemestane (143, compared to 191 with tamoxifen, Table 1). Analyses of incidence of distant 
recurrence and non-breast second primary cancer by age at randomisation reflect data 
presented previously, with a suggestion that second primary cancer incidence increases with 
age but no association was seen between age and distant recurrence incidence (trend tests 
p=0.08 and 0.22 respectively, Appendix 1).  
 
Results of TTDR analyses across the entire follow-up period reflected other efficacy 
endpoints, with an absolute difference in the rate of distant recurrence or breast cancer death 
at 10 years of 2.6% (95% CI 0.2% to 5.1%) and a hazard ratio of 0.84 (95% CI 0.74 to 0.96) 
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in favor of switching to exemestane. Analyses of TTDR after completion of endocrine 
therapy – equivalent to approximately 5 years after diagnosis -  include 4147 patients (2091 
exemestane, 2056 tamoxifen) known to be event free at 2.5 years post-randomisation (Table 
2). No statistically significant difference in TTDR during this period was observed between 
randomised treatment groups (HR=0.94, 95% CI 0.80 to 1.10, p=0.41), reflecting the 
observation that the initial difference in disease outcome observed in the on-treatment period 
is maintained throughout the follow-up period. After inclusion in a multivariable Cox 
proportional hazards model, age at randomisation, nodal status, hormone receptor status, 
previous HRT use and tumor size, but not grade, had a significant effect on the risk of TTDR 
event after completion of endocrine therapy, i.e. of late relapse. Of note, risk of late distant 
recurrence in patients with tumor size greater than 5 cm at diagnosis was almost double that 
of patients with tumors of less than 2 cm (HR=1.92, 95% CI 1.28 to 1.90), and over six times 
higher in patients with 10 or more nodes involved compared to those who were node-negative 
at randomisation (HR=6.10, 95% CI 4.41 to 8.44), after adjustment for other factors.  
 
Fractures 
No statistically significant difference was seen in the proportion of patients reporting at least 
one fracture event in the post-treatment period (exemestane 196/2105 (9.3%), tamoxifen 
163/2036 (8.0%), p=0.14). 
 
Discussion 
This updated and final analysis of IES demonstrates that the benefit associated with switching 
to exemestane observed early in the follow-up period remains undiminished by further 
follow-up. As the IES population ages, incidence of non-breast cancer deaths and non-breast 
second primary cancers increase, leading to a dilution of OS results, however a modest 
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benefit from switching to exemestane can still be seen, with absolute difference in OS at 10 
years post-randomisation of 1.6%. As suggested previously, BCFS (which does not include 
non-breast cancer deaths) remains the most appropriate measure of treatment efficacy in this 
setting; an absolute benefit of 4.0% from switching to exemestane was observed at 10 years. 
Analyses taking into account competing events of intercurrent death and non-breast second 
primary cancer showed an absolute difference in breast cancer event at 10 years of 3%. 
 
The IES trial compared treatments up to 5 years’ duration. Recent large randomised 
controlled trials18-20 have demonstrated an improvement in disease-related outcomes 
associated with continuing tamoxifen or aromatase inhibitor treatment past the standard five 
years of treatment. However long-term use of endocrine therapy is associated with many 
side-effects some of which have substantial impacts on patient well-being such as 
osteoporosis, vasomotor problems and musculo-skeletal conditions21. There remains great 
clinical need to identify patients who remain at high risk of disease relapse after completion 
of 5 years of endocrine therapy who may benefit from further treatment, and conversely 
patients who may be spared this due to low residual risk. 
  
Results of analyses partitioned at 2.5 years post-randomisation support conclusions made 
previously that the difference in disease-related outcome observed at 10 years between 
treatment groups is due to maintenance of the initial on-treatment divergence between groups 
rather than any emerging post-treatment effect. Multivariable analyses of clinical factors 
affecting time to late distant recurrence identified age at randomisation, nodal involvement, 
hormone receptor status, previous HRT use and tumor size, although the relationship between 
HRT use and late distant recurrence is confounded by geographical region. The observation 
that tumor grade no longer retains prognostic significance in this setting after adjustment for 
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other factors reflects previous analyses of retrospective case-series22 and comparable analyses 
of the ATAC trial12. The authors of this analysis also demonstrated the value of the PAM50-
based risk of recurrence (ROR) score as an independent predictor of late distant recurrence; 
other molecular scores studied (IHC4, RS) did not add prognostic information when added to 
clinical data13. 
 
In summary, the IES and other contemporaneous studies have established that a strategy of 
switching to an aromatase inhibitor after 2-3 years of tamoxifen can lead to sustained benefits 
in terms of reduction of disease recurrence and breast cancer mortality. Identifying patients 
who remain at higher risk of disease recurrence after the completion of 5 years of endocrine 
therapy (be it tamoxifen, aromatase inhibitor or a combination of the two) according to 
clinical factors such as nodal involvement and tumor size will aid decision making on the 
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Table and figure legends 
 
Figure 1 = CONSORT diagram 
Figure 2a = Breast cancer free survival in the ER+/unknown population (N=4599) 
Figure 2b = Overall survival in the ER+/unknown population (N=4599) 
Figure 2c = Overall survival in the ITT population (N=4724) 
Figure 2d = Breast cancer specific survival in the ER+/unknown population (N=4599) 
Figure 2e = Disease free survival in the ER+/unknown population (N=4599) 
Figure 3 = Cumulative incidence of breast cancer event and of the competing risks 
intercurrent death and non-breast second cancer 
 
Table 1 = Efficacy events by treatment group in the ER+ve/unknown population (N=4599) 
Table 2 = Factors affecting risk of TTDR event after 2.5 years 
 






















Figure 1: CONSORT diagram 
 
4740 patients randomised




2372 randomised to tamoxifen2352 randomised to exemestane
2294 with ER+/unknown disease 2305 with ER+/unknown disease






















































































Absolute difference at 5 
years = 3.4% 95%CI (1.3, 5.4)
Absolute difference at 10 
years = 4.0% 95%CI (1.2, 6.7)
HR (unadjusted) = 0.81 95%CI (0.72, 0.92); p=0.0006
HR (adjusted) = 0.80 95%CI (0.71, 0.90); p<0.001
Exe 0/2294 55/2193 59/2125 80/2018 70/1919 67/1822 63/1721 51/1643 77/1523 58/1393 53/890 17+0*/35
Tam 0/2305 81/2193 101/2077 98/1948 69/1847 65/1753 72/1651 67/1551 63/1442 49/1333 58/842 19+0*/41
Number of events/at risk
































Absolute difference at 5 years 
= 1.5% 95%CI (-0.3, 3.3)
Absolute difference at 10 years 
= 2.1% 95%CI (-0.5, 4.6)
HR (unadjusted) = 0.89 95%CI (0.78, 1.01); p=0.08
HR (adjusted) = 0.88 95%CI (0.78, 1.01); p=0.06
E = 445/2294
T = 495/2305
Exe 0/2294 17/2229 40/2178 42/2106 63/2010 36/1938 47/1848 43/1774 50/1673 52/1542 43/973 12+0*/36
Tam 0/2305 23/2249 52/2181 53/2094 63/1996 42/1920 62/1825 39/1747 59/1638 52/1518 40/954 10+0*/43
Number of events/at risk




















































Time from randomisation (years)
Exemestane Tamoxifen
Absolute difference at 5 years 
= 1.2% 95%CI (-0.6, 2.9)
Absolute difference at 10 years 
= 1.6% 95%CI (-0.9, 4.1)
HR (unadjusted) = 0.91 95%CI (0.80, 1.03); p=0.15
HR (adjusted) = 0.91 95%CI (0.80, 1.03); p=0.15
E = 467/2352
T = 510/2372
Exe 0/2352 18/2286 41/2234 47/2154 69/2051 38/1977 47/1886 46/1808 52/1703 52/1572 45/991 12+0*/37
Tam 0/2372 24/2314 54/2244 57/2151 65/2049 43/1972 66/1873 39/1794 60/1683 52/1559 40/988 10+0*/46
Number of events/at risk





















Number of events/at risk












Absolute difference at 5 years 
= 1.3% 95%CI (-0.3, 2.8)
Absolute difference at 10 years 
= 2.3% 95%CI (-0.0, 4.6)
HR (unadjusted) = 0.86 95%CI (0.74, 1.00); p=0.03
HR (adjusted) = 0.84 95%CI (0.72, 0.97); p=0.02
E = 303/2294
T = 356/2305
Exe 0/2294 10/2229 25/2178 30/2106 51/2010 34/1938 38/1848 26/1774 32/1673 36/1542 27/973 4+0*/36




























































































Time from randomisation (years)
Exemestane Tamoxifen
Absolute difference at 5 
years = 3.6% 95%CI (1.4, 5.8)
Absolute difference at 10 years 
= 3.8% 95%CI (0.9, 6.6)
E = 650/2294
T = 742/2305
HR (unadjusted) = 0.85 95%CI (0.76, 0.94); p=0.002
HR (adjusted) = 0.83 95%CI (0.75, 0.93); p=0.001
Exe 0/2294 55/2193 59/2125 80/2018 70/1919 67/1822 63/1721 51/1643 77/1523 58/1393 53/890 17+0*/35
Tam 0/2305 81/2193 101/2077 98/1948 69/1847 65/1753 72/1651 67/1551 63/1442 49/1333 58/842 19+0*/41
Number of events/at risk
* events occurring after 11 years
23 
 

















Gray's test for breast cancer event: p=0.002























Time from randomisation (years)
T - Breast cancer event
E - Breast cancer event
T - Non-breast second primary
E - Non-breast second primary
T - Intercurrent death
E - Intercurrent death
Gray's test for breast cancer event: p=0.002
(cf Log Rank test for BCFS: p=0.0006)
Absolute difference at 5 years = 
0.029, 95%CI (0.009, 0.050)
Absolute difference at 10 years = 
0.033, 95%CI (0.007, 0.059)
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Table 1: Efficacy events by treatment group in the ER+ve/unknown population 
(N=4599) 
Number of events contributing  









   
DFS First events 650 (28.3%) 742 (32.2%) 1392 (30.3%) 
      Total BCFS events 508 603 1111 
     Distant recurrence 369 420 789 
     Local recurrence 81 109 190 
     Second primary breast cancer 58 74 132 
     Intercurrent death 142 139 281 
        
All deaths 445 (19.4%) 495 (21.5%) 940 (20.4%) 
     Breast cancer death 263 310 573 
     Death unknown cause 40 46 86 
     Death from other known cause 142 139 281 
Other cancer 40 60 100 
Vascular 36 23 59 
Cardiac 30 23 53 
Other 36 33 69 
        
Distant recurrences 403 (17.6%) 469 (20.4%) 872 (19.0%) 
     Distant recurrence to known site 346 393 739 
Visceral only 129 130 259 
Soft tissue/Nodal only 29 25 54 
Visceral+Soft tissue/Nodal 15 18 33 
          Total sites not including bone 173 173 346 
Bone only 87 127 214 
Visceral+Bone 60 63 123 
Visceral + Bone + Soft tissue/Nodal 15 18 33 
Bone + Soft tissue/Nodal 11 12 23 
          Total sites including bone 173 220 393 
     BC death no previous recurrence 17 28 45 
     Death from unknown cause 40 48 88 
        
Contralateral breast cancers 56 (2.4%) 75 (3.3%) 131 (2.8%) 
        
Non-breast second primary cancers 143 (6.2%) 191 (8.3%) 334 (7.3%) 
     Uterus 15 28 43 
     GI-upper 24 20 44 
     GI-lower 20 28 48 
     Lung 14 29 43 
     Melanoma 10 9 19 
     Ovary 10 8 18 
     Hematological 15 17 32 
     Kidney 5 8 13 






Table 2: Factors affecting risk of TTDR event after 2.5 years (i.e. approximately 5 years after diagnosis) 
  N 
TTDR 
events  
%   
Unadjusted analysis 
  
Adjusted analysis (not including 
geographical region) 
  
Adjusted analysis (including 
geographical region) 
HR 95% CI p-value* HR 95% CI p-value*   HR 95% CI p-value* 
Randomised treatment                       
 
      
Tamoxifen 2056 311 15.1   1 - 
0.41 





Exemestane 2091 300 14.3   0.94 0.80 - 1.10   0.92 0.78 - 1.08 
 
0.92 0.79 - 1.08 
                        
 
      
Age at randomisation                       
 
      
<60 1352 187 13.8   1 - 
0.0003 
  1 - 
0.008  
1 - 
0.004 60-69 1548 248 16.0   1.01 0.84 - 1.22   1.03 0.85 - 1.25 
 
1.05 0.86 - 1.27 
>=70 999 176 17.6   1.43 1.17 - 1.76   1.36 1.09 - 1.70 
 
1.41 1.13 - 1.76 
                        
 
      
Nodal status                       
 
      
N- 2227 183 8.2   1 - 
<0.0001 





1-3N+ 1256 220 17.5   2.22 1.83 - 2.70   2.11 1.72 - 2.59 
 
2.09 1.70 - 2.56 
4-9N+ 386 131 33.9   4.8 3.84 - 6.01   4.41 3.45 - 5.63 
 
4.28 3.35 - 5.46 
>=10N+ 119 57 47.9   7.57 5.63 - 10.21   6.10 4.41 - 8.44 
 
6.07 4.38 - 8.40 
Unknown 159 20 12.6   1.59 1.01 - 2.53   1.63 1.02 - 2.60 
 
1.82 1.14 - 2.92 
                        
 
      
Previous chemotherapy use                       
 
      
Yes 1305 248 19.0   1 - 
<0.0001 





No 2842 363 12.8   0.66 0.56 - 0.77   1.07 0.89 - 1.30 
 
1.06 0.87 - 1.28 
                        
 
      
Hormone receptor status                       
 
      
ER+ and PgR+ 2474 331 13.4   1 - 
0.008 
  1 - 
0.01  
1 - 
0.006 ER+ and PgR-/unknown 1204 206 17.1   1.3 1.09 - 1.55   1.29 1.08 - 1.54 
 
1.33 1.11 - 1.60 
ER unknown and PgR unknown 469 74 15.8   1.24 0.96 - 1.59   1.22 0.94 - 1.58 
 
1.22 0.93 - 1.61 
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  N 
TTDR 
events  
%   
Unadjusted analysis 
  
Adjusted analysis (not including 
geographical region) 
  
Adjusted analysis (including 
geographical region) 
HR 95% CI p-value* HR 95% CI p-value*   HR 95% CI p-value* 
                        
 
      
Histological type                       
 
      
Ductal 3157 450 14.3   1 - 
0.02 
  1 - 
0.30  
1 - 
0.29 Lobular 578 108 18.7   1.32 1.07 - 1.62   1.16 0.93 - 1.45 
 
1.17 0.94 - 1.46 
Other/Unknown 412 53 12.9   0.87 0.65 - 1.16   0.93 0.69 - 1.24 
 
0.93 0.70 - 1.25 
                        
 
      
Previous HRT use                       
 
      
Yes 1021 115 11.3   1 - 
<0.0001 
  1 - 
0.006  
1 - 
0.09 No 3035 473 15.6   1.47 1.20 - 1.80   1.35 1.10 - 1.67 
 
1.20 0.97 - 1.49 
Unknown 91 23 25.3   2.38 1.52 - 3.72   1.74 1.10 - 2.74 
 
1.59 1.00 - 2.52 
                        
 
      
Tumor size (cm)                       
 
      
<=2 2537 277 10.9   1 - 
<0.0001 





>2 & <=5 1431 292 20.4   2.03 1.72 - 2.39   1.51 1.28 - 1.80 
 
1.51 1.27 - 1.79 
>5 94 26 27.7   3.05 2.04 - 4.56   1.92 1.28 - 1.90 
 
1.96 1.30 - 2.96 
Unknown 85 16 18.8   1.76 1.07 - 2.92   1.35 0.80 - 2.25 
 
1.28 0.77 - 2.15 
                        
 
      
Tumor grade                       
 
      
G1 737 73 9.9   1 - 
0.0001 
  1 - 
0.40 
  1 - 
0.69 
G2 1785 263 14.7   1.52 1.17 - 1.97   1.16 0.89 - 1.51   1.14 0.88 - 1.49 
G3/Undifferentiated 756 120 15.9   1.66 1.24 - 2.22   1.16 0.86 - 1.56   1.13 0.84 - 1.53 
Unknown 869 155 17.8   1.91 1.45 - 2.52   1.29 0.96 - 1.72   1.20 0.89 - 1.61 
        
                        
Region       
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  N 
TTDR 
events  
%   
Unadjusted analysis 
  
Adjusted analysis (not including 
geographical region) 
  
Adjusted analysis (including 
geographical region) 
HR 95% CI p-value* HR 95% CI p-value*   HR 95% CI p-value* 
USA 325 26 8.0 
  0.53 0.35 - 0.79 
<0.0001 
          0.67 0.45 - 1.02 
0.02 
UK 512 54 10.5 
  0.63 0.47 - 0.84           0.69 0.51 - 0.94 
Central & Eastern Europe 754 134 17.8 
  1.20 0.98 - 1.46           1.15 0.93 - 1.44 
Rest of Europe 2351 367 15.6 
  1 -           1 - 
Southern Hemisphere & Hong Kong 205 30 14.6 
  1.01 0.70 - 1.47           0.96 0.66 - 1.40 
*- p-value for Likelihood ratio test. p-values are calculated with “unknown” categories included. 
 
